(This is a developing story, so check back for updates.)
In an unprecedented development with revolutionary implications for the American cannabis industry, the U.S. Drug Enforcement Administration is loosening federal restrictions on marijuana and concurring that the drug has medical value, the Associated Press reported Tuesday.
The DEA is agreeing with an August 2023 recommendation from federal health regulators to move cannabis from Schedule 1 to Schedule 3 of the Controlled Substances Act, the AP reported, citing five anonymous sources “familiar with the matter.”
ADVERTISEMENT
The DEA’s decision must now be reviewed by the White House Office of Management and Budget, according to the news service.
“Now the real work begins,” Shane Pennington, an appellate attorney and partner at Washington, D.C.-based Porter Wright, told
Read full article on Marijuana Business Daily
